We serve Chemical Name:N-Sulfinylaniline CAS:1122-83-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-Sulfinylaniline
CAS.NO:1122-83-4
Synonyms:MFCD00002084;N-Thionylaniline, Pract.;Phenylsulfinylamine;Sulfinylphenylamine;Benzenamine, N-sulfinyl-;N-Sulfinylaniline;N-Sulfinylaniline, Pract.;Aniline, N-sulfinyl-;(Sulfinylamino)benzene;EINECS 214-362-4
Molecular Formula:C6H5NOS
Molecular Weight:139.175
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:200.0±9.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.589
PSA:61.52000
Exact Mass:139.009186
LogP:2.58040
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00002084 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 214-362-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenamine, N-sulfinyl- Use and application,(Sulfinylamino)benzene technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 2,6-Dimethyl-4-oxo-1-[4-(1-propyl-butoxy)-phenyl]-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester manufacturers As a global-risk medical practice transforming care of the neediest populations, our centers are located in underserved neighborhoods,” notes Faisel Syed, M.D., ChenMed National Director of Primary Care. (6R,7aR,11aR,11bS)-11-Oxo-5,6,7a,8,9,10,11,11a,11b,12-decahydro-7-oxa-6a,12-diaza-indeno[1,2-a]fluorene-6-carboxylic acid ethyl ester suppliers Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” dimethyl (Z)-2-(2-(2-(2-iodobut-2-en-1-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)ethyl)malonate vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 2,6-Dimethyl-4-oxo-1-[4-(1-propyl-butoxy)-phenyl]-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester manufacturers As a global-risk medical practice transforming care of the neediest populations, our centers are located in underserved neighborhoods,” notes Faisel Syed, M.D., ChenMed National Director of Primary Care. (6R,7aR,11aR,11bS)-11-Oxo-5,6,7a,8,9,10,11,11a,11b,12-decahydro-7-oxa-6a,12-diaza-indeno[1,2-a]fluorene-6-carboxylic acid ethyl ester suppliers Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” dimethyl (Z)-2-(2-(2-(2-iodobut-2-en-1-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)ethyl)malonate vendor & factory.
